Hydroxyethyl-|A-cyclodextrin

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Hydroxyethyl-|A-cyclodextrin
• 英文别名: 1-[[36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecakis(1-hydroxyethoxy)-10,15,20,25,30,35-hexakis(1-hydroxyethoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]ethanol
• 化学式: C₈₄H₁₅₄O₅₆
• 分子量: 2060.1
• InChiKey: TUOVZYHNLDIIMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7
• 重原子数：
  140
• 可旋转键数：
  49
• 环数：
  21.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  748
• 氢给体数：
  21
• 氢受体数：
  56

文献信息

• Soft gelatin capsule formulation
  申请人：KaNDy Therapeutics Limited

  公开号：US10774091B2

  公开（公告）日：2020-09-15

  The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

  本发明一般涉及含有 2-[3,5-双(三氟甲基)苯基]-N-4-(4-氟-2-甲基苯基)-6-[(7S,9aS)-7-(羟甲基)六氢吡嗪并[2,1-c][1,4]恶嗪-8(1H)-基]-3-吡啶基}-N,2-二甲基丙酰胺的新型药物制剂、其制备方法及其在医疗中的用途。
• NOVEL PHARMACEUTICAL FORMULATION
  申请人：KaNDy Therapeutics Limited

  公开号：US20190284205A1

  公开（公告）日：2019-09-19

  The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
• METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE
  申请人：KaNDy Therapeutics Limited

  公开号：US20200361956A1

  公开（公告）日：2020-11-19

  The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis (trifluoromethyl)phenyl]-N-4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
• METHOD OF TREATING CERTAIN SEX HORMONE-DEPENDENT DISEASES ADMINISTERING A SOFT GELATIN CAPSULE COMPRISING NK1 AND NK3 RECEPTORS ANTAGONISTS
  申请人：KaNDy Therapeutics Limited

  公开号：US20200361957A1

  公开（公告）日：2020-11-19

  The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.